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Abstract
Background: In 1999, the American Academy of Pediatrics and U.S. Public Health Service recommended suspending
the birth dose of hepatitis B vaccine due to concerns about potential mercury exposure. A previous report found that
overall national hepatitis B vaccination coverage rates decreased in association with the suspension. It is unknown
whether this underimmunization occurred uniformly or was associated with how providers changed their practices for
the timing of hepatitis B vaccine doses. We evaluate the impact of the birth dose suspension on underimmunization for
the hepatitis B vaccine series among 24-month-olds in five large provider groups and describe provider practices
potentially associated with underimmunization following the suspension.
Methods: Retrospective cohort study of children enrolled in five large provider groups in the United States (A-E).
Logistic regression was used to evaluate the association between the birth dose suspension and a child's probability of
being underimmunized at 24 months for the hepatitis B vaccine series.
Results: Prior to July 1999, the percent of children who received a hepatitis B vaccination at birth varied widely (3% to
90%) across the five provider groups. After the national recommendation to suspend the hepatitis B birth dose, the
percent of children who received a hepatitis B vaccination at birth decreased in all provider groups, and this trend
persisted after the policy was reversed. The most substantial decreases were observed in the two provider groups that
shifted the first hepatitis B dose from birth to 5–6 months of age. Accounting for temporal trend, children in these two
provider groups were significantly more likely to be underimmunized for the hepatitis B series at 24 months of age if they
were in the birth dose suspension cohort compared with baseline (Group D OR 2.7, 95% CI 1.7 – 4.4; Group E OR 3.1,
95% CI 2.3 – 4.2). This represented 6% more children in Group D and 9% more children in Group E who were
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underimmunized in the suspension cohort compared with baseline. Children in the reversal cohort in these groups
remained significantly more likely to be underimmunized compared with baseline. In contrast, in a third provider group
where the typical timing of the third dose was unchanged and in two other provider groups whose hepatitis B vaccination
schedules were unaffected by the birth dose suspension, hepatitis B vaccination coverage either was maintained or
improved.
Conclusion: When the hepatitis B birth dose was suspended, provider groups that moved the first dose of vaccination
to 5–6 months of age or later had decreases in hepatitis B vaccine coverage at 24 months. These findings suggest that as
vaccine policy changes occur, providers could attempt to minimize underimmunization by adopting vaccination schedules
that minimize delays in the recommended timing of vaccine doses.
Background
In 1999, the Food and Drug Administration determined
that cumulative exposure to mercury through vaccination
exceeded one of three existing federal safety guidelines for
methylmercury exposure for some children[1,2]. While
information was limited regarding the potential adverse
effects of exposure through childhood vaccination to
thimerosal, a preservative in vaccines that is metabolized
into ethylmercury, [1,2] the American Academy of Pediat-
rics (AAP) and the United States Public Health Service (US
PHS) issued a Joint Statement in July 1999 to describe sev-
eral key actions intended to assure the replacement of
thimerosal-containing vaccines with thimerosal-free for-
mulations while encouraging the maintenance of child-
hood vaccination coverage levels[3]. In this Statement,
they recommended as an additional precaution the tem-
porary deferment of the first dose of hepatitis B vaccine
until 2–6 months of age for infants born to hepatitis B sur-
face antigen-negative women. Specific recommendations
for timing of the second and third doses in the hepatitis B
vaccine series were not provided. By mid-September 1999,
the first thimerosal-free hepatitis B vaccine was licensed in
the United States, and a second statement was issued rec-
ommending the reinstatement of hepatitis B birth vacci-
nation practices in hospital nurseries[4].
The rapid reversal in the hepatitis B birth dose recommen-
dations may have led to unanticipated disruptions in
immunization delivery. Timing of the first dose of hepati-
tis B vaccine had previously been associated with a child's
up-to-date status at later ages[5]. While hospital nurseries
quickly discontinued routine administration of a hepatitis
B vaccine birth dose following the July 1999 Joint State-
ment, reinstatement of birth vaccination policies had
failed to reach pre-July 1999 levels one year after the new
thimerosal-free hepatitis B vaccine first became available
[6-8]. In addition, a disruption in hepatitis B vaccination
coverage following the birth dose suspension was
observed in a nationally representative sample of 19-
month olds[9].
It is unknown whether pediatricians' decisions about how
to shift the recommended ages of the hepatitis B doses
affected the likelihood that their patients would fail to
complete this vaccine series. Understanding how different
adjustments to childhood immunization recommenda-
tions may affect vaccine series completion, when changes
are needed, is important because such changes have
become more frequent in recent years due to vaccine
shortages and new vaccines. Our study was designed to
address this key issue by evaluating how the hepatitis B
vaccine birth dose suspension affected immunization cov-
erage rates among the patients of five large provider
groups with varying vaccination policies both before and
after the suspension.
Methods
Study population
This study included the membership of five large provider
groups: Harvard Vanguard Medical Associates (Boston,
MA), HealthPartners (Minneapolis, MN), Kaiser Perma-
nente of Colorado (Denver, CO), Kaiser Permanente of
Northern California (Oakland, CA), and Kaiser Perma-
nente Northwest (Portland, OR). These sites participate in
the Centers for Disease Control and Prevention Vaccine
Safety Datalink Project, in which individual-level vaccina-
tion, demographic, and medical data are shared to facili-
tate vaccine safety and other vaccine-related
epidemiologic research [10-12].
We studied infants who were born between October 1,
1996 and December 31, 1999, who were continuously
enrolled in one of the five provider groups from birth
through their second year of life, and who received at least
one polio vaccination. The continuous enrollment criteria
was applied to ensure that the most complete immuniza-
tion history was available, while receipt of polio vaccina-
tion was used as an indicator that a child received
immunizations that were recorded in the provider group
information systems. The study protocol was approved by
the institutional review boards at the participating pro-
vider groups and the Centers for Disease Control and Pre-
vention.BMC Pediatrics 2006, 6:31 http://www.biomedcentral.com/1471-2431/6/31
Page 3 of 9
(page number not for citation purposes)
Definition of exposure and outcome
Each child was assigned to one of three exposure birth
cohorts, based on the timing of their birth relative to the
issuance and subsequent reversal of the thimerosal-
related birth dose suspension recommendations. Chil-
dren born between October 1, 1996 and June 30, 1999
were grouped in the "baseline" cohort. Children born
between July 1, 1999 and September 30, 1999 were
assigned to the birth dose "suspension" cohort, the period
when the thimerosal-related recommendations were in
effect[4]. Children born between October 1, 1999 and
December 31, 1999 were grouped in the hepatitis B policy
"reversal" cohort, denoting a period following withdrawal
of the birth dose suspension recommendations.
The outcome, underimmunized for the hepatitis B vaccine
series, was defined as the receipt of fewer than the three
recommended doses of hepatitis B vaccine at 24 months
of age (yes/no). Vaccinations that were administered
before the minimum recommended age or earlier than
the minimum recommended between-vaccination inter-
val, allowing for a four-day grace period[13,14], were con-
sidered to be invalid. Only the remaining vaccinations for
eligible individuals were included in our analysis.
Statistical analysis
To evaluate the association between the hepatitis B policy
reversals and hepatitis B underimmunization status at age
24 months, odds ratios and 95% confidence intervals (CI)
were calculated from logistic regression models. A linear
trend based on birth month cohort was included to adjust
for temporal trend. We also tested whether temporal trend
varied by policy period; interaction by policy period was
not statistically significant, and these additional terms
were not included in the final model. To aid interpreta-
tion of the logistic regression results, predicted probabili-
ties were output from the logistic regression model for two
time points (July 1999 and October 1999 birth cohorts).
For each time point, the absolute difference in hepatitis B
underimmunization at age 24 months was calculated by
comparing the percent of children underimmunized as
fitted from the regression model and observed data, to the
predicted percent underimmunized based on extrapola-
tion from the pre-suspension baseline cohort of children
born between October 1996 – June 1999 (i.e., absolute
difference = [fitted % underimmunized] - [predicted %
underimmunized]) (Figure 1).
All analyses were performed using SAS software, Version
8.2 of the SAS System for Windows (SAS Institute, Cary,
NC).
Results
Study population
Of the 214,499 children born and enrolled at birth in the
five provider groups during the study period, 87,447 were
continuously enrolled through their 24-month birthday.
Of these children, 85,064 (97.3%) received at least one
polio vaccination. Preliminary data audits revealed two
subgroups of children for whom immunization histories
were potentially incomplete: (1) children who were born
during a potential disruption in the immunization track-
ing system during the early baseline period in one pro-
vider group (Group B) (n = 4,112) and (2) children in a
second provider group (Group C) who received vaccina-
tions in a set of outpatient clinics for which information
on health care utilization was identified as likely to be
incomplete (n = 651). Exclusion of these children resulted
in a final population of 80,301 children.
Variation in hepatitis B birth vaccination practices
Prior to the birth dose suspension, administration of hep-
atitis B vaccination within the first week of life ("birth"
vaccination) varied widely across the provider groups
(Figure 2). While 4% of children in Group A and 3% in
Group B received a hepatitis B birth dose, 49% of children
in Group C, 90% in Group D, and 89% in Group E did so.
After the birth dose suspension, children in all five pro-
vider groups were less likely to receive a hepatitis B birth
dose, with children in Group D and Group E experiencing
substantial declines that persisted even after reversal of the
suspension recommendations (baseline vs. suspension vs.
reversal Group D: 90% vs. 13% vs. 11%; Group E: 89% vs.
13% vs. 9%).
Impact of the birth dose suspension on failure to complete 
the hepatitis B vaccine series by 24 months
In Groups A, B, and C, the percent of children who were
underimmunized for the hepatitis B vaccine series at 24
months remained similar or decreased following the birth
dose suspension (Group A: 6% baseline vs. 5% suspen-
sion vs. 7% reversal, χ2 p = 0.42; Group B: 11% vs. 5% vs.
4%, χ2 p < 0.0001; Group C: 12% vs. 10% vs. 9%, χ2 p <
0.0001)(Table 1). In contrast, children were generally
more likely to be underimmunized for the hepatitis B vac-
cine series at 24 months following the birth dose suspen-
sion in Group D (7% baseline vs. 9% suspension vs. 8%
reversal, χ2 p = 0.09) and in Group E (9% baseline vs. 14%
suspension vs. 11% reversal, χ2 p = 0.0002).
Adjusting for temporal trend in the logistic regression
analysis yielded similar findings to the unadjusted results
(Table 2). In Provider Group A, immunization coverage
among 24 month olds remained similar before and fol-
lowing the hepatitis B birth dose suspension recommen-
dations. In Provider Groups B and C, children were less
likely to be underimmunized in both the suspensionBMC Pediatrics 2006, 6:31 http://www.biomedcentral.com/1471-2431/6/31
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period (Table 2) and the reversal period (data not shown)
compared to the pre-suspension baseline. In contrast,
children in Group D and Group E were significantly more
likely to be underimmunized for the hepatitis B series at
24 months during the suspension period (Table 2), repre-
senting 6% more children in Group D and 9% more chil-
dren in Group E who were underimmunized for hepatitis
B vaccine in the July 1999 birth dose suspension cohort
compared to that predicted from baseline. Children in
these two provider groups remained significantly more
likely to be underimmunized in the reversal period
(Group D OR = 2.5, 95% CI: 1.4 – 4.5; Group E OR = 2.7,
95% CI: 1.9 – 3.9), representing 5% more children in
Group D and 7% more children in Group E who were
underimmunized in the October 1999 birth cohort com-
pared to that predicted from baseline.
Variation in the timing of hepatitis B vaccinations
Further assessment of the scheduling of hepatitis B vacci-
nation indicated that the typical timing of all three doses
in the hepatitis B vaccine series varied across the five pro-
vider groups, both during the baseline period and follow-
ing the hepatitis B birth dose suspension (Table 2). In
Groups A and B, where hepatitis B vaccination at birth was
infrequent, children born following the birth dose sus-
pension typically received their hepatitis B vaccine doses
at similar or earlier ages compared to the baseline cohort.
In Group C, where 49% of children received a hepatitis B
birth vaccination but where an improvement in hepatitis
B immunization coverage among 24-month-olds was
observed, slight shifts toward delayed receipt of the first
and second doses occurred during the suspension period;
at the same time, the most common timing of the third
Calculation of predicted absolute differences in percent of 24-month-olds underimmunized for the hepatitis B vaccine series,  birth dose suspension and reversal periods versus baseline Figure 1
Calculation of predicted absolute differences in percent of 24-month-olds underimmunized for the hepatitis B 
vaccine series, birth dose suspension and reversal periods versus baseline. --- : % children underimmunized based on 
logistic regression model and the observed data. - - - - : % children underimmunized predicted from the baseline. Time point 
a: July 1999 birth cohort, start of the birth dose suspension period. Δ1 compares % children underimmunized for the July 1999 
birth cohort based on the fitted data to that predicted from the baseline. Time point b: October 1999 birth cohort, following 
reversal of the birth dose suspension. Δ2 compares % children underimmunized for the hepatitis B vaccine series for the Octo-
ber 1999 birth cohort based on the fitted data to that predicted from baseline.BMC Pediatrics 2006, 6:31 http://www.biomedcentral.com/1471-2431/6/31
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dose remained at age 5–6 months (38% baseline vs. 31%
suspension) or age 9–10 months (24% baseline vs. 28%
suspension). In contrast, while 89–90% of children in
Group D and Group E had received a hepatitis B vaccina-
tion at birth during the baseline period, the most com-
mon age at receipt of the first hepatitis B vaccination was
shifted to 5–6 months of age during the birth dose sus-
pension (62% in each Group). In these two provider
groups, delays and less uniformity in the timing of the sec-
ond and third dose of hepatitis B vaccine were also
observed during the birth dose suspension (Table 2; Fig-
ure 3). Children born in these provider groups during the
baseline period typically received the second dose of hep-
atitis B vaccine by 2 months of age (92% in Group D; 85%
in Group E) and the third dose, between 7–10 months of
age in Group D (70%) and 5–6 months of age in Group E
(67%). Among the birth dose suspension cohort, the age
at receipt of the second dose was most commonly shifted
to 9–10 months and the third dose, to 11–12 months of
age or later. Delays in the timing for the three hepatitis B
Percent of children enrolled in five large U.S. provider groups who received a first hepatitis B vaccination within the first week  of life, October 1996 – December 1999 Figure 2
Percent of children enrolled in five large U.S. provider groups who received a first hepatitis B vaccination 
within the first week of life, October 1996 – December 1999. Baseline cohort: born between October 1996 – June 
1999 (n = 67,835). Birth dose suspension cohort: born between July 1999 – September 1999 (n = 6,401). Reversal cohort: 
born between October 1999 – December 1999 (n = 6,065).
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doses in these provider groups were similar in the reversal
period to that observed during the suspension period
(data not shown).
Discussion
This study found that in the populations of five large pro-
vider groups, hepatitis B vaccine coverage decreased after
national recommendations to suspend the birth dose, but
only in those provider groups that shifted the first dose of
hepatitis B from birth to 5–6 months of age or later. These
disruptions in immunization scheduling and coverage
persisted after approval of the first thimerosal-free hepati-
tis B vaccine. In contrast, immunization coverage
remained the same or improved over the same time
period in settings that experienced either no change or
minor shifts in the typical timing of hepatitis B vaccina-
tions following the birth dose suspension recommenda-
tions.
Our findings may shed light on how providers can choose
the optimal ways to shift the timing of vaccines when
national committees make changes in the routine immu-
nization schedule. Many vaccine schedule changes have
been issued in recent years due to concerns about thime-
rosal, vaccine shortages, and the introduction of new vac-
cines [15-17]. Our findings confirm those of Luman et
al.,[9] who found declines in birth vaccination as well as
in national hepatitis B coverage rates among 19-month-
olds associated with the birth dose suspension. Our
results go beyond the previous study to suggest that dis-
ruptions in coverage were associated with local baseline
policies that determined whether provider practices
needed to be modified in response to the birth dose sus-
pension, and with how different provider groups changed
the timing of hepatitis B vaccine doses in response to the
suspension. Major disruptions following the birth dose
suspension were restricted to those sites where universal
hepatitis B birth vaccination had been the dominant pre-
existing practice. Furthermore, increases in hepatitis B
underimmunization among 24 month olds were seen
only in sites where the first dose was commonly delayed
by at least 5 months. With this delay in administration of
the first dose, scheduling typically observed during the
baseline period for the second (≤2 months) and third (5–
6 months or 9–10 months) doses could not be followed
during the birth dose suspension. Provider practices at the
other sites showed minimal or no downstream adjust-
ments in immunization scheduling. Similar to Luman et
al.,[9] we found no consistent patterns in immunization
coverage for other childhood vaccine series in relation to
the hepatitis B policy reversals (data not shown).
Some of the hepatitis B coverage changes we observed
across these settings could have been due to other local
setting influences. For example, two of the provider
groups used a combination hepatitis B-Hib vaccine which
is recommended at 2, 4, and 12–15 months of age[13].
The combination hepatitis B-Hib vaccine was available in
Group A throughout the entire study period, and this pro-
vider group neither changed the timing of its doses nor
experienced a significant change in hepatitis B underim-
munization in response to the suspension. Group B began
use of the combination hepatitis B-Hib vaccine around
the time of the hepatitis B birth dose suspension. This may
have contributed to the shift toward earlier ages for receipt
of the third hepatitis B vaccine dose and the improved
coverage rates in this group.
This study was conducted among a small sample of large
provider groups, with populations that had insurance and
good access to primary care. These results may not gener-
alize to other settings, uninsured populations or groups
with worse access to care. We also restricted the study pop-
ulation to children who were continuously enrolled dur-
ing the first two years of life and had at least one polio
vaccination recorded in the provider group information
systems; these children are likely to have experienced less
scattering of their immunization records and to have had
more opportunities to catch up on immunizations. Thus,
the decreases in hepatitis B coverage we observed in two
Table 1: Change in practices for the hepatitis B birth dose and underimmunization at age 24 months
Absolute difference in % children who received 1st 
hepatitis B vaccination during first week of life
% underimmunized for hepatitis B vaccine series at age 24 months, unadjusted 
results
Suspension vs. Baseline Reversal vs. Baseline Baseline Suspension Reversal
Group A -2% -4% 6% 5% 7%
Group B -1% -2% 11% 5% 4%
Group C -35% -28% 12% 10% 9%
G r o u p  D - 7 7 % - 7 9 % 7 %9 %8 %
Group E -76% -80% 9% 14% 11%
"Birth vaccination" is defined as receipt of a hepatitis B vaccination between 0 and 7 days of age. Baseline cohort: Born between October 1996 – 
June 1999 (n = 67,835). Birth dose suspension cohort: Born between July – September 1999 (n = 6,401). Reversal cohort: Born between October 
– December 1999 (n = 6,065).BMC Pediatrics 2006, 6:31 http://www.biomedcentral.com/1471-2431/6/31
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of our study's provider groups might be larger in more
vulnerable populations.
Conclusion
We conclude that substantially delaying the timing of the
first hepatitis B vaccination dose in response to the
nationally recommended birth dose suspension may be
associated with downstream disruptions in immunization
coverage. This suggests that as vaccine policy changes
occur, providers may be able to minimize underimmuni-
zation by adopting vaccination schedules that minimize
delays in the recommended timing of vaccine doses.
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Table 2: Typical age(s) at receipt of hepatitis B vaccine doses and change in % underimmunized at 24 months for the hepatitis B 
vaccine series, baseline vs. birth dose suspension cohorts, children enrolled in five large U.S. provider groups, October 1996 – 
December 1999
Modal Age in Months at Hepatitis B 
Vaccination*
Group Exposure cohort Dose 1 Dose 2 Dose 3 Predicted Absolute Change in % 
Underimmunized at 24 Months in the 
Suspension vs. Baseline Period†
OR for Being Underimmunized at 24 
Months in the Suspension vs. Baseline 
Period (95% CI)§
AB a s e l i n e : ≤2 3–4 11–12 -2% 0.7 (0.4 – 1.3)
Suspension: ≤2 3–4 11–12
BB a s e l i n e : ≤2 ≤21 7 – 1 8 - 5 % ‡ 0.5 (0.2 – 0.9)
Suspension: ≤2 3–4 11–12
CB a s e l i n e : B i r t h ≤25 – 6 - 3 % ‡ 0.8 (0.7 – 0.9)
Suspension: ≤23 – 4 5 – 6
DB a s e l i n e : B i r t h ≤2 9–10 +6%‡ 2.7 (1.7 – 4.4)
Suspension: 5–6 9–10 15–16
EB a s e l i n e : B i r t h ≤25 – 6 + 9 % ‡ 3.1 (2.3 – 4.2)
Suspension: 5–6 9–10 11–12
*Baseline cohort: Born between October 1996 – June 1999 (n = 67,835). Birth dose suspension cohort: Born between July – September 1999 (n = 
6,401). Age at vaccination was grouped into the following categories: birth (0–7 days), ≤ 2 months (8 days – 2 months), 3–4 months, 5–6 months, 7–
8 months, 9–10 months, 11–12 months, 13–14 months, 15–16 months, 17–18 months, 19–20 months, 21–24 months, and did not receive dose by 
24 months. For each dose, the most common ages at vaccination were listed.
† For each provider group, the predicted absolute difference was calculated comparing the % hepatitis B underimmunized at age 24 months among 
the July 1999 birth cohort as fitted from multivariate regression models adjusting for temporal trend versus the % underimmunized as extrapolated 
from baseline (i.e., absolute difference = [fitted % underimmunized]July1999 - [predicted % underimmunized]July1999).
‡ p < 0.05.
§ ORs are from logistic regression models adjusted for temporal trend.BMC Pediatrics 2006, 6:31 http://www.biomedcentral.com/1471-2431/6/31
Page 8 of 9
(page number not for citation purposes)
Delays in age at receipt of hepatitis B vaccine doses among children enrolled in provider groups D and E following the hepatitis  B birth dose suspension recommendations, baseline cohort vs. birth dose suspension cohort Figure 3
Delays in age at receipt of hepatitis B vaccine doses among children enrolled in provider groups D and E fol-
lowing the hepatitis B birth dose suspension recommendations, baseline cohort vs. birth dose suspension 
cohort. - - - : Baseline cohort of children born between October 1996 – June 1999 (n = 67,835).  : Birth dose suspension 
cohort of children born between July – September 1999 (n = 6,401). Age at vaccination was grouped into the following catego-
ries: birth (0–7 days), < 2 months (8 days – 2 months), 3–4 months, 5–6 months, 7–8 months, 9–10 months, 11–12 months, 
13–14 months, 15–16 months, 17–18 months, 19–20 months, 21–24 months, and did not receive dose by 24 months ("never").
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